A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis

被引：0

作者：

Merkel, Peter A. ^{[1
]}

Niles, John ^{[2
]}

Jimenez, Richard ^{[3
]}

Spiera, Robert F. ^{[4
]}

Rovin, Brad H. ^{[5
]}

Bomback, Andrew ^{[6
]}

Pagnoux, Christian ^{[7
]}

Potarca, Antonia ^{[8
]}

Schall, Thomas J. ^{[9
]}

Bekker, Pirow ^{[9
]}

机构：

[1] Univ Penn, Div Rheumatol, Perelman Sch Med, Philadelphia, PA 19104 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Univ Washington Med, Northwest Hosp & Med Ctr, Seattle Arthrit Clin, Rheumatol, Seattle, WA USA

[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[5] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[6] Columbia Univ, Med Ctr, New York, NY USA

[7] Univ Toronto, Univ Hlth Network, Mt Sinai Hosp, Div Rheumatol, Toronto, ON, Canada

[8] ChemoCentryx Inc, Mountain View, CA USA

[9] ChemoCentryx, Mountain View, CA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

978

引用

页数：2

共 50 条

[41] Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients - a Study of Routine Clinical Practice in the EU
Rutherford, Peter
Goette, Dieter
Stamm, Melinda
Liu, Xierong
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[42] Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: results of a Phase 2 randomized, double-blind, placebo-controlled trial
Howard, J. F.
Nowak, R. J.
Wolfe, G. I.
Benatar, M. G.
Macdougall, J.
Duda, P. W.
Far, R. Farzaneh
Kaminski, H. J.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 41 - 41
[43] Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial
Merkel, Peter A.
Jayne, David R.
Wang, Chao
Hillson, Jan
Bekker, Pirow
JMIR RESEARCH PROTOCOLS, 2020, 9 (04):
[44] Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Tapson, Victor E.
Torres, Fernando
Kermeen, Fiona
Keogh, Anne M.
Allen, Roblee P.
Frantz, Robert P.
Badesch, David B.
Frost, Adaani E.
Shapiro, Shelley M.
Laliberte, Kevin
Sigman, Jeffrey
Arneson, Carl
Galie, Nazzareno
CHEST, 2012, 142 (06) : 1383 - 1390
[45] Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
Huffman, Brandon M.
Mallick, Atrayee Basu
Horick, Nora K.
Wang-Gillam, Andrea
Hosein, Peter Joel
Morse, Michael A.
Beg, Muhammad Shaalan
Murphy, Janet E.
Mavroukakis, Sharon
Zaki, Anjum
Schlechter, Benjamin L.
Sanoff, Hanna
Manz, Christopher
Wolpin, Brian M.
Arlen, Philip
Lacy, Jill
Cleary, James M.
JAMA NETWORK OPEN, 2023, 6 (01) : E2249720
[46] Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Tapson, Victor F.
Jing, Zhi-Cheng
Xu, Kai-Feng
Pan, Lei
Feldman, Jeremy
Kiely, David G.
Kotlyar, Eugene
McSwain, C. Shane
Laliberte, Kevin
Arneson, Carl
Rubin, Lewis J.
CHEST, 2013, 144 (03) : 952 - 958
[47] Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled trial and open-label long-term extension
Howard, James F., Jr.
Nowak, Richard J.
Wolfe, Gil I.
Benatar, Michael G.
Duda, Petra W.
MacDougall, James
Farzaneh-Far, Ramin
Kaminski, Henry J.
NEUROLOGY, 2019, 93 (05) : E533 - E534
[48] Low Complement C3 Levels at Diagnosis of ANCA-Associated Glomerulonephritis, a Specific Subset of Patients to Target With Anti-C5aR Therapy? In response to: Hypocomplementemia at Diagnosis of Pauci-immune Glomerulonephritis Is Associated with Advanced Histopathological Activity Index and High Probability of Treatment Resistance (Lionaki et al., Kidney International Reports, June 2021, DOI: 10.1016/j.ekir.2021.05.043)
Brilland, Benoit
Wacrenier, Samuel
Henry, Nicolas
Guibert, Fanny
Piccoli, Giorgina Barbara
Augusto, Jean-Francois
KIDNEY INTERNATIONAL REPORTS, 2021, 6 (11): : 2931 - 2933
[49] SUSTAINED VIROLOGIC RESPONSE AND POSTTREATMENT LIVER FUNCTION ARE ASSOCIATED WITH 5-YEAR SURVIVAL AFTER DIRECT-ACTING ANTIVIRAL TREATMENT IN DECOMPENSATED CIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS: A LONG-TERM FOLLOW UP STUDY OF JAPANESE CLINICAL TRIAL COHORT
Tahata, Yuki
Hikita, Hayato
Takaki, Akinobu
Kurosaki, Masayuki
Matsuura, Kentaro
Yatsuhashi, Hiroshi
Kuroda, Hidekatsu
Ueno, Yoshiyuki
Kodama, Takahiro
Sakamori, Ryotaro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2024, 80 : S344 - S345
[50] An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Huang, Chung-Feng
Hung, Chao-Hung
Cheng, Pin-Nan
Bair, Ming-Jong
Huang, Yi-Hsiang
Kao, Jia-Horng
Hsu, Shih-Jer
Lee, Pei-Lun
Chen, Jyh-Jou
Chien, Rong-Nan
Peng, Cheng-Yuan
Lin, Chun-Yen
Hsieh, Tsai-Yuan
Cheng, Chun-Han
Dai, Chia-Yen
Huang, Jee-Fu
Chuang, Wan-Long
Yu, Ming-Lung
JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (04): : 557 - 566

← 1 2 3 4 5 →